Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics Inc (VTGN) is a clinical-stage biopharmaceutical company pioneering neuroscience-focused treatments through innovative stem cell technology. This page provides investors and industry professionals with essential updates on the company’s progress, including press releases, clinical trial milestones, and strategic developments.
Access real-time information on VTGN’s advancements in predictive toxicology, drug metabolism screening, and neuropsychiatric therapies. Our curated news collection ensures you stay informed about regulatory submissions, partnership announcements, and financial disclosures without needing to track multiple sources.
Key updates include progress in stem cell-derived bioassay systems, FDA communications regarding therapeutic candidates, and insights into the company’s unique approach to in vitro testing. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for streamlined access to VTGN’s latest developments. Check back regularly for authoritative reporting on advancements in neuroscience and biotechnology that could shape the future of drug discovery.
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company, has appointed Elissa Cote as Chief Corporate Development Officer. With nearly 30 years of experience, Cote will lead strategic opportunities and partnerships for Vistagen's pherine platform, which includes five novel intranasal candidates targeting six prevalent disorders.
Prior to joining Vistagen, Cote served as fractional Chief Business Officer and held senior roles at Mallinckrodt Pharmaceuticals, Sucampo Pharmaceuticals, and MedImmune. As part of her appointment, she received an incentive option to purchase 150,000 shares of Vistagen's common stock, vesting over four years.
Vistagen (VTGN), a late clinical-stage biopharmaceutical company focused on neuroscience and developing intranasal pherine products, has announced its participation in the upcoming Jefferies 2025 Global Life Sciences Conference in New York. The company's CEO, Shawn Singh, will engage in a fireside chat on June 5, 2025, at 11:40 a.m. ET. Investors can access the presentation through a live webcast on Vistagen's website's Investors section, with a replay available afterward.
[]Vistagen (VTGN), a clinical-stage biopharmaceutical company focused on neuroscience, will present two posters at the American Society of Clinical Psychopharmacology (ASCP) Conference in Scottsdale, Arizona from May 27-30, 2025. The first presentation on May 28 will discuss the age of onset of Social Anxiety Disorder (SAD) from fasedienol clinical trials. The second presentation on May 29 will explore how itruvone, their investigational pherine for major depressive disorder, affects nasal chemosensory receptors and olfactory bulb physiologic activation through specific biomarkers. Both posters will be available on Vistagen's website on June 2, 2025.
Vistagen (VTGN) presented new research on Social Anxiety Disorder (SAD) at the 2025 ADAA Conference, building on findings from the 2024 NEI Congress. The research reveals that SAD affects nearly 31 million U.S. adults, with increasing prevalence especially among young adults aged 18-22.
Key findings show that while SAD prevalence has increased, diagnosis rates remain stagnant and treatment rates have decreased. Over 20% of adults with SAD reported suicidal ideation, and 75% experienced mild to severe depression. In the 18-22 age group, 48.1% reported suicidal ideation, showing higher depression rates and worse mental health outcomes than those without SAD.
Data from Vistagen's fasedienol PALISADE Phase 3 studies revealed that 30% of participants had SAD onset at age 10 or younger, with an average 27-year delay before first treatment. The research emphasizes the urgent need for improved diagnosis, treatment options, and social support mechanisms.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and nose-to-brain neurocircuitry, will present at the Anxiety and Depression Association of America (ADAA) Conference in Las Vegas from April 3-5, 2025.
The company will showcase two poster presentations focusing on social anxiety disorder (SAD):
- On April 4, 2025: Research on age of onset of SAD in fasedienol (PH94B) nasal spray trials (Poster F40)
- On April 5, 2025: A cross-sectional study examining SAD among young adults aged 18-22 using US National Health and Wellness Survey data (Poster S109)
Both posters will be made available on Vistagen's website on April 7, 2025. The presentations highlight the company's work with pherines, a new class of intranasal product candidates.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and nose-to-brain neurocircuitry, has announced its participation in the upcoming Stifel 2025 Virtual CNS Forum. The company's President and CEO, Shawn Singh, will engage in a fireside chat presentation on March 18, 2025, at 12 p.m. Eastern Time.
The company specializes in developing and commercializing a novel class of intranasal product candidates called pherines. Interested parties can access the live webcast through the 'Events' page in the 'Investors' section of Vistagen's website, with a replay available after the event.
Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company focused on neuroscience and pherine development, has announced its participation in the 45th Annual TD Cowen Healthcare Conference. The company's President and CEO, Shawn Singh, will deliver a corporate overview on Monday, March 3, 2025, at 2:30 p.m. Eastern Time.
The presentation will be accessible via webcast through the 'Events' page in the 'Investors' section of Vistagen's website. Investors and interested parties can access the replay of the webcast, which will be archived on the company's website after the event.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
